UK HealthTech Startup Nul Secures €840,000 Seed to Expand Alcohol Reduction Platform

Key Facts on Nul's Seed Funding:

• Amount Raised: €840,000 Seed
• Lead Investors: dmg ventures, BYVP
• Core Clinical Strategy: Naltrexone and behavioral support (Sinclair Method)
• Goal: UK commercial launch and future US market entry

Nul, a London-based digital health startup focused on alcohol consumption reduction services, announced a €840,000 ($1 million approximately) Seed funding round to support its UK commercial launch, expand operations, and lay groundwork for international growth.

Who Funded Nul's Reduction Platform?

The financing was led by dmg ventures, the corporate venture arm of Daily Mail and General Trust, and BYVP, joined by angel investors from technology, healthcare, and consumer sectors. The capital is earmarked for hiring clinical and product staff, customer acquisition, and future market entry, including the United States.

How Does Nul's Alcohol Reduction Model Work?

Founded by Matus Maar, former co-founder of Talis Capital and current CEO of Nul, the platform combines remote clinical consultations, prescription services, and structured digital pathways to assist users seeking to reduce alcohol intake.

The core programme centres on naltrexone, an FDA-approved opioid antagonist medication used in treatment protocols for alcohol use disorder. Nul’s service is subscription-based and delivered entirely online, with structured behavioural support influenced by The Sinclair Method, a pharmacological “extinction” approach designed to weaken the reinforcement of alcohol consumption.

Nul combines telehealth, medication, and behavioral science to address alcohol use disorder.

What Is the Medical Context for Naltrexone?

Naltrexone has regulatory approval in the United States and other jurisdictions for alcohol use disorder and has been shown in clinical research to reduce cravings and consumption compared to placebo in several measures of drinking behaviour.

The Sinclair Method, developed from scientific research on reward pathways, prescribes taking naltrexone prior to alcohol exposure to block reinforcing neurochemical effects and gradually reduce the compulsion to drink. Evidence and expert communities note that outcomes can vary and that the approach is not universally recommended as first-line treatment in clinical guidelines due to mixed high-quality evidence.

What is the Market Traction So Far?

Nul reports it initiated a UK test phase in summer 2025, onboarding over 120 paying customers and achieving an annualised revenue run-rate near €344,000. The company plans a public crowdfunding campaign on Republic Europe to involve retail investors in the next growth phase and anticipates further fundraising in 2026 as scale increases.

Why is the UK HealthTech Sector Attracting Capital?

The UK health technology sector has attracted substantial investor interest, with combined startup valuations reaching tens of billions of pounds in recent years, reflecting broader digital health and consumer health technology momentum.

What is the Future Outlook for Digital Health?

Digital and remote approaches to alcohol reduction reflect broader shifts in health provision towards telehealth, consumer-centric treatment, and technology-enabled behavioural support. As companies like Nul expand, they may influence how services intersect with traditional care pathways and regulatory environments, but the clinical and public health communities continue to emphasize a range of evidence-based strategies rather than single methods or tools.